Alzamend Neuro, Inc.
ALZNNasdaq
$1.21
↓ -0.8%Jul 17 close · end-of-day
Price
1Y↓ -65.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$4.6M
Enterprise Value
$1.9M
P/E
0.4
P/S
—
P/B
2.1
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$7.0M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-322.4%
ROIC
—
Debt / Equity
—
Net Cash
$2.7M
Return 1Y
-64.6%
Company profile
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative diseases and psychiatric disorders. The company was incorporated in 2016 and is headquartered in Atlanta, Georgia.
- CEO
- Stephan Jackman
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 4
- Headquarters
- Georgia
- Website
- alzamend.com
Earnings
ALZN Q3 2026 Earnings
Period ends 2026-01-31
MetricActualYoY
Revenue——
Diluted EPS-$0.58↓ -66.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$5.0M | -$12.3M | -$14.9M | -$9.9M | -$4.5M |
| Net income | -$5.0M | -$12.4M | -$14.9M | -$9.9M | -$4.5M |
| Diluted EPS | — | -$0.14 | -$22.89 | -$132.33 | -$11.32 |
| Operating cash flow | -$2.7M | -$6.6M | -$8.9M | -$8.3M | -$6.6M |
| Free cash flow | — | — | — | — | — |
| Gross margin | — | — | — | — | — |
| Operating margin | — | — | — | — | — |
| Net margin | — | — | — | — | — |
| Line item | Q4 '24 | Q1 '24 | Q2 '24 | Q3 '25 | Q4 '25 | Q1 '25 | Q2 '25 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$850,062.00 | -$962,405.00 | -$1.4M | -$1.0M | -$1.1M | -$2.7M | -$998,109.00 | -$2.2M |
| Net income | -$851,529.00 | -$974,411.00 | -$1.4M | -$1.0M | -$1.1M | -$2.7M | -$1.0M | -$2.2M |
| Diluted EPS | -$118.75 | -$11.42 | -$3.61 | -$1.75 | $5.46 | -$1.28 | -$0.30 | -$0.58 |
| Operating cash flow | -$1.4M | -$1.1M | -$3.4M | -$1.4M | -$688,705.00 | -$2.4M | -$1.2M | -$1.7M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jan 26, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-04-14 | AULT MILTON C III | Buy | 108,388 | $1.00 | $108,897.42 | filing |
| 2025-12-23 | AULT MILTON C III | Sale | 1,851 | $2.07 | $3,825.09 | filing |
| 2025-12-19 | Horne William B | Sale | 3,333 | $2.12 | $7,058.63 | filing |
| 2025-10-23 | McGrath Lynne Fahey | Sale | 30 | $2.29 | $68.70 | filing |
| 2025-10-09 | AULT MILTON C III | Sale | 20,397 | $2.32 | $47,390.39 | filing |
| 2025-10-08 | AULT MILTON C III | Sale | 101,394 | $2.44 | $247,158.01 | filing |
| 2025-10-08 | AULT MILTON C III | C | 61,743 | $2.32 | $143,243.76 | filing |
| 2025-10-07 | AULT MILTON C III | C | 100,000 | $2.32 | $232,000.00 | filing |
| 2025-10-07 | AULT MILTON C III | Sale | 57,379 | $2.49 | $142,954.04 | filing |
| 2025-10-06 | AULT MILTON C III | Sale | 82,033 | $2.45 | $201,267.97 | filing |
| 2025-10-03 | AULT MILTON C III | C | 100,000 | $2.32 | $232,000.00 | filing |
| 2025-10-03 | AULT MILTON C III | Sale | 65,903 | $2.44 | $160,888.99 | filing |
| 2025-10-02 | AULT MILTON C III | Sale | 20,686 | $2.39 | $49,522.28 | filing |
| 2025-10-01 | AULT MILTON C III | C | 100,000 | $2.32 | $232,000.00 | filing |
| 2025-10-01 | AULT MILTON C III | Sale | 36,777 | $2.35 | $86,378.14 | filing |
| 2025-09-30 | AULT MILTON C III | Sale | 3,566 | $2.33 | $8,320.90 | filing |
| 2025-09-29 | AULT MILTON C III | Sale | 38,324 | $2.31 | $88,490.12 | filing |
| 2025-09-26 | AULT MILTON C III | Sale | 37,738 | $2.31 | $87,344.60 | filing |
| 2025-09-25 | AULT MILTON C III | C | 100,000 | $2.32 | $232,000.00 | filing |
| 2025-09-25 | AULT MILTON C III | Sale | 14,628 | $2.31 | $33,828.71 | filing |
| 2025-09-24 | AULT MILTON C III | Sale | 39,140 | $2.31 | $90,374.26 | filing |
| 2025-09-23 | AULT MILTON C III | Sale | 43,238 | $2.38 | $102,720.52 | filing |
| 2025-09-22 | AULT MILTON C III | C | 100,000 | $2.32 | $232,000.00 | filing |
| 2025-09-19 | AULT MILTON C III | Sale | 77,009 | $2.35 | $180,855.64 | filing |
| 2025-09-18 | AULT MILTON C III | Sale | 20,870 | $2.47 | $51,492.55 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.